Status:
COMPLETED
Sinus Augmentation With Allograft-Bone Substitute in Severe Maxillary Atrophy
Lead Sponsor:
Can Tho University of Medicine and Pharmacy
Conditions:
Implant Site Reaction
Eligibility:
All Genders
Phase:
NA
Brief Summary
This study was conducted in two phases. In Phase 1, lateral window sinus floor augmentation was performed using a mixture of hydroxyapatite (30%) and β-tricalcium phosphate (70%) combined with autolog...
Detailed Description
Phase 1: Lateral window sinus floor augmentation, bone graft The patient was prescribed a prophylactic antibiotic regimen consisting of Amoxicillin with Clavulanic Acid (1 g Augmentin tablet), taken o...
Eligibility Criteria
Inclusion
- Patients with a residual bone height ≤4 mm
- minimum prosthetic space of 5 mm
Exclusion
- Patients with acute or chronic maxillary sinusitis, bleeding disorders, diabetes mellitus, bone metabolic diseases, periodontal disease, or malignancies were excluded.
- taking medications that could affect bone metabolism or hemostasis
- Smokers and pregnant women were also excluded from the study.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT07186166
Start Date
January 1 2022
End Date
February 1 2024
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Can Tho University of Medicine and Pharmacy
Can Tho, Vietnam, 90000